Thursday, October 8, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 25, 2026

Billionaire Bill Ackman Sold This Stock While Warren Buffett Successor Greg Abel Bought It. Who's Right?

View original at finance.yahoo.com
Billionaire Bill Ackman Sold This Stock While Warren Buffett Successor Greg Abel Bought It. Who's Right? Bill Ackman is one of the most followed investment managers in the market today, and for good reason…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Gemini family of models are among the most performant on the market

    60% confidence

  • Alphabet's AI models are better at understanding search intent, improving ad targeting

    60% confidence

  • Search revenue growth continues to accelerate, up 19% in the most recent quarter, driven by AI product improvements and underlying model advances

    60% confidence

  • Google Cloud revenue growth accelerated to 63% last quarter and operating margin expanded to 33%, with total operating income tripling

    60% confidence

  • AI Overview has led to significant increases in engagement while maintaining the same level of monetization

    60% confidence

  • Pershing Square Holdings produced annualized returns of 14.9% from founding in 2004 through 2025, handily beating the S&P 500

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com